Fig. 5.

Proportion of patients with three-month confirmed disability progression in patients with highly active RRMS or less active RRMS for DAC HYP vs. placebo. Highly active RRMS was defined as at least two relapses in the year prior to randomization and at least one gadolinium-enhancing lesion at baseline, all other patients comprised the less active RRMS subgroup. CI confidence interval, DAC HYP daclizumab high-yield process, RRMS relapsing-remitting multiple sclerosis. ^a p-values and percentage reduction for DAC HYP vs. placebo were estimated from a Cox proportional hazards model controlling for baseline EDSS (≤2.5 vs. >2.5) in each disease activity subgroup